FMI's market valuation priced at $400 million vs. CLRX's $9 million....FMI will likely trade north and head towards $1 billion shortly. CLRX may actually have a better mousetrap in genetic / cancer information intelligence, although CLRX does not have the proprietary lab tests that FMI is also developing. Will be interesting to follow...and see if CLRX can capture market share once they make more progress. Right place, right time. Now, CLRX needs to execute.
Sorry, wrongly said Foundation Health instead of Foundation Medicine. Company now valued at about $1 Billion, having doubled in its IPO debut. By contrast, CLRX is actually closer to around $13 million, not $9 million, as I misstated before.
Lots of upside if CLRX can execute...
Agree 100%...buying all dips now. Patent news is extremely positive. Opens door for major partnership or buyout. Plus, Qysmia is the most effective drug and 3-year studies will be out in the next few months, which should show reduced cardiovascular risk and reduced diabetes risk. There are 100 million obese people in the U.S. This entire cleft palet issue impacts 4 million women who are pregnant. Eventually, they no longer want babies and are still overweight, so they come back into the patient population. Belviq's studies show less efficacy than Qsymia...that is a 100% fact, no matter what people say on this board. Now that distribution has been increased, it is only a matter of time before scripts increase. There's multiple catalysts coming.
Agree 100%...looking to add more shares on any dip. This news is game-changing to the standard of diabetes care.
Scripts will move higher. If you are a fund manager, you will need to explain to your shareholders why you didn't cover at $10.50 when the stock is $50 by June 2014
Qsymia = best efficacy of weight loss, strong safety profile and simply a better drug than anything on the market (no matter what you say, Qsymia is better than ARNA and OREX's drugs). The cleft issue impacts 4 million pregnant women per year vs. 100 million + overweight people - it's a NON-issue. Qsymia reduces the incidence of diabetes by 70%-80% in high-risk patients - that's better than Lipitor against cholesterol. And, the patent protection takes this drug out to 2028.
You're crazy if you're short. What are you looking at? The past year of scripts...stupid. The ballgame is different. You got the first out, but bases are loaded and Hank Aaron is at the plate. You're starting pitcher is about to get bombed. Once news of Qsymia and diabetes makes there way through the medical community, now that distribution issues are largely behind VVUS (remember it was mail order only for months), the scripts will rocket higher.
Keep shorting. I hope you get your backside soon feels like a pole was put inside of it.
SNTA's goal in its latest trial was to limit phase III risk by finding those patients who have the highest probability for strong outcomes in phase III...essentially, personalized medicine! This is significant. The trial had some issues, with Eastern European patients from two countries entering in the final six months, which likely skewed the data so it wasn't as robust as the drug had performed in earlier trials. But, the fact is that the idea being finding a homogeneous group of trial patients is the future of biotech trial work.
You will see going forward, an increasing use of genomics data to screen patients to find the proper group of patients to enter into late stage clinical trials based on earlier stage trial work. As screening tests continue to proliferate for all sorts of cancers and demographic, geographic and timing effectiveness (i.e. the SNTA drug is only effective when given after 6 months of first line effort) get factored into trial design, you will see significant increases in drug outcomes vs. placebo. A more targeted trial cohort is a major step forward in finding effective drugs to treat specific patient populations.
Very forward thinking trial work. Worth adding here...
Because ONE test, Cancer of Unknown Origin impacts 200,000 people per year and the reimbursement has been set at $3,500 per test. That's a $700 million market alone.
Once the patent news hits officially in 2 weeks, whichever it is, LOOK OUT ABOVE....buyout bids for VVUS will be coming into Management....not just partnership deals. Accumulate BIG on this weakness.
That's impressive. CLRX will get paid for every one of Life Technologies and Quest Diagnostic genetic tests going forward.
CLRX now worth less than $15 million fully diluted.
Short all you want. Keep shorting. Create the biggest short position you can. Please do it. Pretty please. With sugar and cherry on top.
LIFE and DGX do not enter into these agreements unless there is a compelling reason.
The future of diagnostic medicine will have every patient being genetically tested, just like you get blood work done in your annual physicals. Then, patients with cancer, will be further tested to see which patients should get which cancer drugs. Both Roche and Glaxo, for example, are partnering with diagnostic firms to create genetic tests for the protein and enzyme deficiencies or surpluses that are involved in many different cancer types. With the human genome being solved, these genetic tests will go down to the nano level, eventually. And, not only do most physicians not have the time to keep up with the medical literature in medical journals, but the confusion that will be created from the magnitude of tests, therapies and trials, creates an enormous need to have information available giving a clear path of interpretation. That is what CLRX information helps provide...consolidated information from experts to help advise doctors in the field on what to do, what to do next and what's available given the plethora of information.
LIFE and DGX are two of the biggest genetic testing firms in the world and they chose to partner with CLRX, who will make money on each test, as the lab reports of all these tests will include the CLRX information. This data HAS to become standard practice...there is just too much information and not enough time in the day for physicians and other healthcare practitioners to read and understand what's available.
The value of what CLRX is doing...information...is extremely high. It helps decision making, cuts time, personalizes medicine, and saves money.
$15 million market cap....CLRX will be the next 100-bagger.
All these shorts acting like some boiler room is pumping CLRX. Hello! There was actually BIG news to justify a major move up....and it's going higher...MUCH HIGHER. You don't sign LIFE and DGX and not have a compelling value software / data product. PERIOD. END OF STORY. NO MATTER WHAT YOU SHORTS ARGUE OR SAY. PROOF IS IN THE DEALS.
How is a pump and dump the result of signing a multi-billion dollar diagnostic firm? It's called really good news. The stock got dumped because it's not in strong hands, there are former Tegal shareholders selling at any pop, and a bunch of daytraders taking advantage. The more volume, the better. Shares will move into stronger hands.
So, you're saying they made up the press release with Quest? So, they don't have both LIFE and Quest as customers? So, you're saying it's all baloney. Give me a break, dude. You know something, if they placed 2 million shares at $4.00 with a healthcare fund, I would be 100% happy about that dilution. Because then that firm would be incentivized to support the stock. There are too many guys like you hanging around here. Too many weak hands. Too many daytraders. Too many shorts. One day soon, the stock will gap open and run, and you'll be calling your friends to borrow money to meet a margin call on your short. Keep shorting.
There won't be a revenue ramp until 2014 as that's when the LIFE deal starts kicking in to go along with their increased focus on developing a major testing business. The focus of the call tomorrow should be on how the LIFE deal is progressing, more info on the Quest deal, whether the rollout of the mobile Everyday Health app is ready, what the cash balance / usage / need is going forward, and how to attract better investors...which as you can tell, from all the news pops over the past year, since Tegal bought CollabRx, the result is a gap up in the stock price and massive shorting back down...every single time. So, the stock needs to be in much stronger hands so that the next pop keeps going. This business is worth well more than $12 million. Imagine CLRX was privately held, and they were coming public with Life Technologies and Quest Diagnostics as two of their customers and Everyday Health (similar to WebMD) as a partner. Valuation would be significantly higher. For the stock to be below where it was trading prior to the Quest news speaks to the weak shareholder base and the easy manipulation that can be done with a low float stock. So, this is a key focus going forward. I would welcome dilution to a group of healthcare focused funds, providing CLRX cash and an investor base that would support the stock.
Non Exclusive enables CLRX to sign deals with other labs, otherwise, it would be a one-customer shop.
C'mon bro...give it up.